Compare TTGT & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTGT | OBIO |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.8M | 238.9M |
| IPO Year | 2024 | 2020 |
| Metric | TTGT | OBIO |
|---|---|---|
| Price | $4.47 | $3.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $10.75 | ★ $14.25 |
| AVG Volume (30 Days) | ★ 349.8K | 201.3K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $33,482,000.00 |
| Revenue This Year | $4.45 | N/A |
| Revenue Next Year | $2.75 | $12.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $3.37 | $2.20 |
| 52 Week High | $7.37 | $5.42 |
| Indicator | TTGT | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 60.80 | 51.19 |
| Support Level | $3.52 | $3.77 |
| Resistance Level | $4.75 | $4.18 |
| Average True Range (ATR) | 0.33 | 0.17 |
| MACD | 0.11 | 0.03 |
| Stochastic Oscillator | 83.27 | 68.52 |
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. The company provides marketing and sales services that deliver business impact for enterprise technology companies. It develops editorial content across multiple technology-focused websites and channels to engage audiences researching information technology solutions. The company generates revenue by providing market insight and market access to the technology market, including enterprise technology, artificial intelligence, channel, cybersecurity, media & entertainment, and service providers. Geographically, it derives the majority of revenue from North America.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.